N/A N=90

PERIODONTAL DISEASE AND HYPERLIPIDEMIA

Hyperlipidemia, Periodontitis, Gingivitis

Bottom Line

View on ClinicalTrials.gov: NCT02808130 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Sep 2016

Primary outcome: Primary: Gingival Crevicular Fluid Level of Malondialdehyde (MDA) as a Marker of Lipid Oxidation. — 144.09; 298.52; 802.09; 139.50 pg/ml

Study Design & Population

Study type: Observational
Phase: N/A
Interventions: hyperlipidemia, periodontitis, gingivitis (Other)
Age: Adult · 18+ yrs
Sex: All
Sponsor: Ondokuz Mayıs University
Primary completion: Aug 2014

Outcome Measures

Outcome	Result	p-value
PRIMARY Gingival Crevicular Fluid Level of Malondialdehyde (MDA) as a Marker of Lipid Oxidation.	144.09; 298.52; 802.09; 139.50; 292.98; 899.73	—
PRIMARY Protein Carbonyl Level in Gingival Crevicular Fluid as a Marker of Protein Oxidation	0.05; 0.31; 1.91; 0.07; 0.41; 2.89	—
PRIMARY Total Antioxidant Capacity Levels in Gingival Crevicular Fluid as a Marker of Antioxidant Status	92.21; 78.32; 69.70; 90.32; 70.58; 54.12	—

Summary

The investigators hypothesized that hyperlipidemia as an unfavourable levels of lipoprotein subfractions have deleterious impact on the development of periodontal infection by altering oxidative stres status of periodontal tissues. The aim of this study was therefore to investigate i) effect of hyperlipidemia on oxidative change in GCF content, ie. MDA, PC and TAOC levels in patients with different periodontal status,

Eligibility Criteria

Inclusion Criteria

(i) ≥ 18 years of age and having ≥ 16 teeth; (ii)no periodontal therapy in the 6 months prior to data collection; (iii) no systemic problems or chemotherapy within the 6 weeks prior to data collection and any anti-lipaemic drug treatment; (iv) no previous history of smoking.

Exclusion Criteria

(i) medical history of cancer, rheumatoid arthritis, diabetes mellitus, or cardiovascular disease and any other systemic disease affecting lipid metabolism(i.e. impaired glucose tolerance, metabolic syndrome); (ii) compromised immune system; (iii) pregnancy, menopause, or lactation; (iv) ongoing drug therapy that might affect the clinical characteristics of periodontitis and lipid metabolism; (v) use of systemic antimicrobials during the 6 weeks prior to data collection; and (vi) dental treatment during the 6 months prior to data collection.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02808130). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.